» Articles » PMID: 33312457

The Impact of Patent Expiry on Drug Prices: Insights from the Dutch Market

Overview
Publisher MDPI
Specialty Public Health
Date 2020 Dec 14
PMID 33312457
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

: Currently literature on the impact of patent expiry on drug prices is lacking. : To determine the impact of patent expiration and generic entry on drug prices in the Netherlands. : Prescription and price data from 1999 up to and including December 2016 were collected from two national databases. The overall price ratio of drugs prices up to 48 months after patent expiration was compared to the price in the month before expiry. Sub-analyses were performed to provide insights in generic uptake, length of market exclusivity and price development for originators and generics separately. : In total 250 drugs faced patent expiration during the study period. Forty-eight months after patent expiration the median price ratio decreased to 0.59 (IQR = 0.23-0.86) compared to the month prior patent expiry. Major differences in price developments were observed depending on the level of revenue prior to patent expiration and the time of patent expiration with ratios ranging from 0.08 (IQR = 0.07-0.16) to 0.81 (IQR = 0.62-0.97). Prior to patent expiry, the price decreased by 2.3% annually while having market exclusivity for 11.3 years on average. : This study showed that the median drug price after patent expiration decreased by 41% after 4 years. The results of this study can be used to provide more reliable estimates on drug prices over its lifecycle and can be implemented in economic evaluations to inform the cost-effectiveness and long-term budget impact of new drugs.

Citing Articles

Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy.

Centanni M, Nijhuis J, Karlsson M, Friberg L Pharmacoeconomics. 2024; 43(1):31-43.

PMID: 39327347 PMC: 11724784. DOI: 10.1007/s40273-024-01438-z.


Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses.

Serra-Burriel M, Martin-Bassols N, Perenyi G, Vokinger K JAMA Health Forum. 2024; 5(8):e242530.

PMID: 39150730 PMC: 11329876. DOI: 10.1001/jamahealthforum.2024.2530.


GEFormerDTA: drug target affinity prediction based on transformer graph for early fusion.

Liu Y, Xing L, Zhang L, Cai H, Guo M Sci Rep. 2024; 14(1):7416.

PMID: 38548825 PMC: 10979032. DOI: 10.1038/s41598-024-57879-1.


The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands.

Kirshner G, Makai P, Brouns C, Timmers L, Kemp R Eur J Health Econ. 2024; 25(7):1147-1163.

PMID: 38190008 PMC: 11377641. DOI: 10.1007/s10198-023-01648-w.


Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran.

Fens T, de Jong L, Kappelhoff B, Boersma C, Postma M J Mark Access Health Policy. 2023; 11(1):2247719.

PMID: 37675057 PMC: 10478629. DOI: 10.1080/20016689.2023.2247719.


References
1.
Vogler S, Habl C, Bogut M, Voncina L . Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J. 2011; 52(2):183-97. PMC: 3081217. DOI: 10.3325/cmj.2011.52.183. View

2.
Morgan S, Vogler S, Wagner A . Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy. 2017; 121(4):354-362. DOI: 10.1016/j.healthpol.2017.02.002. View

3.
Vondeling G, Cao Q, Postma M, Rozenbaum M . The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review. Appl Health Econ Health Policy. 2018; 16(5):653-660. PMC: 6132437. DOI: 10.1007/s40258-018-0406-6. View

4.
Fens T, van der Pol S, Kocks J, Postma M, van Boven J . Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. Value Health. 2019; 22(10):1092-1101. DOI: 10.1016/j.jval.2019.05.006. View